Sunshine Biopharma Inc.
Close on Oct 19, 2026
- Market cap
- $330.14K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | Apr 9, 2026 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 2, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $8.44M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 19, 2024 | After market close | $9.30M | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 1, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 13, 2023 | Before market open | $5.96M | $-0.04 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 11, 2023 | Before market open | $5.56M | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 11, 2023 | After market close | $4.89M | – | – |
Press releases
Announcements Sunshine Biopharma filed with the SEC
On Thursday, October 08, 2026 at 8:00 AM ET
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Closing of up to $20.4 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
PRESS RELEASE, DATED MAY 18, 2026
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED MAY 19, 2026
Material agreement · Other events · EX-99.2 to Form 8-K
Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Results of operations · EX-99.1 to Form 8-K
ENGAGEMENT AGREEMENT BETWEEN THE COMPANY AND AEGIS
Other events · EX-99.1 to Form 8-K
Sunshine Biopharma Reports 2025 First
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 2, 2025
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED APRIL 3, 2025
Material agreement · Other events · EX-99.2 to Form 8-K
Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Results of operations · EX-99.1 to Form 8-K
SUNSHINE BIOPHARMA REPORTS 2024 THIRD QUARTER
Results of operations · EX-99.1 to Form 8-K
SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER
Results of operations · EX-99.1 to Form 8-K
SUNSHINE BIOPHARMA REPORTS 2024 FIRST QUARTER
Results of operations · EX-99.1 to Form 8-K
BIOPHARMA REPORTS OPERATING RESULTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
Results of operations · EX-99.1 to Form 8-K
PRESS RELEASE DATED FEBRUARY 13, 2024
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE DATED FEBRUARY 15, 2023
Material agreement · Other events · EX-99.2 to Form 8-K
OVER LAST YEAR DUE TO A KEY ACQUISITION
Results of operations · EX-99.1 to Form 8-K
SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION
Other events · EX-99.1 to Form 8-K
SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER
Results of operations · EX-99.1 to Form 8-K
Sunshine Biopharma Announces Pricing of $5.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Sunshine Biopharma Announces Closing of $5.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%
Results of operations · EX-99.1 to Form 8-K
SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLpro-BASED COVID-19 TREATMENT
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biopharma ANNOUNCES THE ACQUISITION OF NORA PHARMA,
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
FINANCIAL STATEMENTS OF NORA PHARMA, INC.
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE ISSUED ON APRIL 26, 2022
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Sunshine Biopharma, Inc. Announces Closing of $19.5 Million Private
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
FORM OF AMENDMENT TO WARRANT
Other events · EX-99.1 to Form 8-K
PRESS RELEASE ISSUED MAR 10, 2022
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Closing of $8.0 Million Private Placement Priced At-the-Market
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 15, 2022
Material agreement · Other events · EX-99.1 to Form 8-K
PRESS RELEASE, DATED FEBRUARY 17, 2022
Material agreement · Other events · EX-99.2 to Form 8-K
Sunshine Biopharma Inc. (OTC Markets: SBFM)
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces $1,361,000 in Debt Reduction
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Independent Directors Added as Part of Company’s
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K